{"product_id":"dxcm-business-model-canvas","title":"DexCom, Inc. (DXCM): Business Model Canvas [June-2026 Updated]","description":"\u003cp\u003eThis ready-made Business Model Canvas for DexCom, Inc. gives you a practical, research-based view of how the Company creates, delivers, and captures value through the \u003cstrong\u003eG7 15-Day CGM platform\u003c\/strong\u003e, the \u003cstrong\u003eStelo biosensor\u003c\/strong\u003e, and a user base of \u003cstrong\u003e3.5 million active users\u003c\/strong\u003e, backed by \u003cstrong\u003e$2.4 billion\u003c\/strong\u003e in cash and expanded manufacturing capacity. You'll see its main growth drivers, including CGM R\u0026amp;D, software development, global expansion, and partnerships such as ŌURA app integration, Tandem Mobi compatibility, Signos distribution, and RAMQ reimbursement in Québec, along with the key customer segments, channels, revenue streams, and cost pressures that shape the business.\u003c\/p\u003e\u003ch2\u003eDexCom, Inc. - Canvas Business Model: Key Partnerships\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eDexCom, Inc.\u003c\/strong\u003e depends on partnerships that connect its continuous glucose monitoring data to devices, software, insurers, and reimbursement systems. These relationships matter because they extend distribution, raise product utility, and improve patient access without DexCom having to build every channel itself.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003ePartnership area\u003c\/th\u003e\n\u003cth\u003eBusiness role\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eŌURA app integration\u003c\/td\u003e\n\u003ctd\u003eConsumer and metabolic health data integration\u003c\/td\u003e\n \u003ctd\u003eExpands DexCom data use beyond glucose reading into sleep, activity, and wellness workflows\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTandem Mobi pump compatibility\u003c\/td\u003e\n\u003ctd\u003eConnected diabetes device ecosystem\u003c\/td\u003e\n\u003ctd\u003eSupports automated insulin delivery and increases switching costs for users\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSignos distribution agreement\u003c\/td\u003e\n\u003ctd\u003eDigital health and weight-management channel\u003c\/td\u003e\n \u003ctd\u003eBroadens access to non-insulin metabolic health users and coaching-based programs\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRAMQ reimbursement in Québec\u003c\/td\u003e\n\u003ctd\u003ePublic payer access\u003c\/td\u003e\n\u003ctd\u003eImproves affordability and prescription adoption in a provincial reimbursement system\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner ecosystem for metabolic health\u003c\/td\u003e\n\u003ctd\u003ePlatform expansion\u003c\/td\u003e\n\u003ctd\u003eCreates a network effect around CGM data, apps, pumps, coaches, and payers\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eŌURA app integration\u003c\/strong\u003e is important because it links glucose data with a consumer health platform focused on sleep, activity, and recovery. For DexCom, this partnership supports a wider use case than insulin management alone. It helps position continuous glucose monitoring as part of everyday metabolic health tracking, which is relevant for users who want to connect food, exercise, sleep, and glucose patterns in one place.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIt expands the audience beyond people already managing insulin.\u003c\/li\u003e\n \u003cli\u003eIt supports user retention because data becomes more useful when it sits inside a broader health app.\u003c\/li\u003e\n \u003cli\u003eIt strengthens DexCom's role as a data layer rather than only a sensor maker.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eTandem Mobi pump compatibility\u003c\/strong\u003e is a core strategic partnership because it ties DexCom CGM data to automated insulin delivery. The value here is operational, not just technical. When CGM data feeds a pump system, the user gets a tighter loop between sensing and insulin dosing, which makes the combined system harder to replace.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIt supports patient stickiness through device interoperability.\u003c\/li\u003e\n \u003cli\u003eIt increases the clinical value of DexCom data in diabetes treatment.\u003c\/li\u003e\n \u003cli\u003eIt helps DexCom stay embedded in physician-recommended diabetes technology stacks.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eSignos distribution agreement\u003c\/strong\u003e supports DexCom's move into metabolic health beyond traditional diabetes care. Signos is built around CGM-guided coaching and behavior change, so the relationship gives DexCom exposure to users interested in weight management, nutrition, and lifestyle feedback. This matters because it opens a channel where glucose data is used for daily decision-making, not only disease management.\u003c\/p\u003e\n\n\u003cp\u003eThe partner model also helps DexCom reach consumers through a service layer. Instead of selling only to clinics, hospitals, and pharmacies, DexCom can reach users through digital programs that package CGM with coaching and tracking tools.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRAMQ reimbursement in Québec\u003c\/strong\u003e matters because reimbursement reduces out-of-pocket cost barriers. In public payer markets, coverage can influence whether a patient starts CGM and whether a prescriber prefers one device over another. For DexCom, provincial reimbursement is not just a sales issue. It is a market access issue that affects adoption speed, prescription volume, and competitive position in Canada.\u003c\/p\u003e\n\n\u003cp\u003ePublic reimbursement also changes the economics of the partnership network. When a payer covers CGM, manufacturers, distributors, pharmacies, and clinicians all operate with a lower affordability hurdle, which can support steadier demand.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePartner ecosystem for metabolic health\u003c\/strong\u003e is the broader business logic behind all of these relationships. DexCom is building a network where glucose data can move across consumer apps, insulin pumps, coaching platforms, and reimbursement channels. That makes the company more than a hardware supplier. It becomes a data platform with multiple endpoints.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003ePartner type\u003c\/th\u003e\n\u003cth\u003eExamples\u003c\/th\u003e\n\u003cth\u003eStrategic impact on DexCom\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumer health apps\u003c\/td\u003e\n\u003ctd\u003eŌURA\u003c\/td\u003e\n\u003ctd\u003eRaises engagement and broadens daily use cases\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInsulin delivery devices\u003c\/td\u003e\n\u003ctd\u003eTandem Mobi\u003c\/td\u003e\n\u003ctd\u003eImproves clinical utility and device lock-in\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital coaching and distribution\u003c\/td\u003e\n\u003ctd\u003eSignos\u003c\/td\u003e\n\u003ctd\u003eAdds direct-to-consumer reach and lifestyle-health positioning\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic payers\u003c\/td\u003e\n\u003ctd\u003eRAMQ\u003c\/td\u003e\n\u003ctd\u003eImproves access and lowers patient cost barriers\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinics and prescribers\u003c\/td\u003e\n\u003ctd\u003eEndocrinology and primary care networks\u003c\/td\u003e\n\u003ctd\u003eDrives clinical adoption and repeat prescribing\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThis ecosystem matters because DexCom's value increases when more partners use the same glucose data in different ways. A pump partner uses it for insulin automation. A consumer app uses it for behavior tracking. A payer uses it for access control. A coaching platform uses it for habit change.\u003c\/p\u003e\n\n\u003cp\u003eThe strategic effect is that DexCom can create multiple revenue paths from one core product category. That lowers dependence on a single channel and supports broader market penetration across diabetes care and metabolic health.\u003c\/p\u003e\u003ch2\u003eDexCom, Inc. - Canvas Business Model: Key Activities\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003e$3.62 billion\u003c\/strong\u003e in 2023 revenue, \u003cstrong\u003e$486.5 million\u003c\/strong\u003e in research and development expense, and \u003cstrong\u003e$1.46 billion\u003c\/strong\u003e in selling, general, and administrative expense frame the scale of the main operating activities.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eActivity area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eReal-life numbers and dates\u003c\/strong\u003e\u003c\/td\u003e\n \u003ctd\u003e\u003cstrong\u003eWhy it matters\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCGM R\u0026amp;D and product launches\u003c\/td\u003e\n\u003ctd\u003e$486.5 million R\u0026amp;D expense in 2023; G7 U.S. launch in 2023; Stelo FDA clearance in March 2024\u003c\/td\u003e\n \u003ctd\u003eSupports sensor accuracy, new form factors, and new customer segments\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing expansion\u003c\/td\u003e\n\u003ctd\u003e$159.8 million capital expenditures in 2023; $1.23 billion cash and cash equivalents at December 31, 2023\u003c\/td\u003e\n \u003ctd\u003eSupports higher sensor output, supply reliability, and unit-cost control\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftware and app development\u003c\/td\u003e\n\u003ctd\u003eApple Watch integration, smartphone apps, and remote-sharing features across G7 and Stelo product lines\u003c\/td\u003e\n \u003ctd\u003eImproves user retention, clinician use, and ecosystem stickiness\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory compliance and recalls\u003c\/td\u003e\n\u003ctd\u003eFDA clearance for Stelo in March 2024; quality-system controls required across U.S., EU, and other markets\u003c\/td\u003e\n \u003ctd\u003eDetermines market access and lowers product, labeling, and reporting risk\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal distribution and market expansion\u003c\/td\u003e\n \u003ctd\u003e2023 revenue outside the U.S. was \u003cstrong\u003e$1.32 billion\u003c\/strong\u003e; U.S. revenue was \u003cstrong\u003e$2.30 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003ctd\u003eShows dependence on global reimbursement, distributors, and local launches\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCGM R\u0026amp;D and product launches\u003c\/strong\u003e are the core activity because DexCom has to keep improving continuous glucose monitoring accuracy, wear time, and ease of use. In 2023, R\u0026amp;D expense was \u003cstrong\u003e$486.5 million\u003c\/strong\u003e, equal to about \u003cstrong\u003e13.4%\u003c\/strong\u003e of revenue ($486.5 million ÷ $3.62 billion). That level of spending shows that product development is not a side task; it is the main driver of future sales. The most important launch activity was G7 in the U.S. in 2023, followed by Stelo FDA clearance in \u003cstrong\u003eMarch 2024\u003c\/strong\u003e. Stelo matters because it opened a new category: adults not using insulin.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eManufacturing expansion\u003c\/strong\u003e is a required activity because CGM is a high-volume sensor business. DexCom reported \u003cstrong\u003e$159.8 million\u003c\/strong\u003e in capital expenditures in 2023, which signals ongoing investment in production capacity, equipment, and supply chain infrastructure. The company also ended 2023 with \u003cstrong\u003e$1.23 billion\u003c\/strong\u003e in cash and cash equivalents, which supports factory spending and working capital needs. For a CGM company, manufacturing is not only about making more units; it is about maintaining yield, lowering defects, and avoiding stock-outs when launches scale quickly.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$159.8 million\u003c\/strong\u003e capital expenditures in 2023\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e$1.23 billion\u003c\/strong\u003e cash and cash equivalents at December 31, 2023\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e$3.62 billion\u003c\/strong\u003e total revenue in 2023\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eSoftware and app development\u003c\/strong\u003e is a key activity because the sensor alone does not create the full customer experience. DexCom's apps, data-sharing tools, and device integrations connect readings to phones, watches, caregivers, and clinicians. This matters because CGM value depends on real-time visibility, alerts, and usability. In practice, software supports retention: if a user's glucose data is easy to see and share, the product becomes harder to replace. It also supports clinician adoption because remote data review makes treatment decisions easier.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eFinancial item\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2023 amount\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.62 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost of sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.23 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross profit\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.39 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and development\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$486.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSelling, general, and administrative\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.46 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRegulatory compliance and recalls\u003c\/strong\u003e are unavoidable activities because CGM products are medical devices. DexCom's U.S. expansion into over-the-counter CGM required FDA clearance for Stelo in \u003cstrong\u003eMarch 2024\u003c\/strong\u003e. That is a regulatory milestone, but it also means the company must maintain ongoing compliance for labeling, adverse event reporting, quality systems, and post-market monitoring. In this business, even small defects can trigger corrective action because sensors are used daily and at scale. Regulatory work therefore protects market access and revenue continuity.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eGlobal distribution and market expansion\u003c\/strong\u003e are key activities because DexCom sells into multiple geographies with different reimbursement and regulatory rules. In 2023, U.S. revenue was \u003cstrong\u003e$2.30 billion\u003c\/strong\u003e, while non-U.S. revenue was \u003cstrong\u003e$1.32 billion\u003c\/strong\u003e. That split shows a broad international business but also continued reliance on the U.S. market. Global expansion requires local approvals, distributor management, reimbursement work, and launch execution by country. It also affects manufacturing planning because international demand adds complexity to forecasting and inventory allocation.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eU.S. revenue in 2023: \u003cstrong\u003e$2.30 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n \u003cli\u003eNon-U.S. revenue in 2023: \u003cstrong\u003e$1.32 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n \u003cli\u003eTotal revenue in 2023: \u003cstrong\u003e$3.62 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n \u003cli\u003eR\u0026amp;D expense in 2023: \u003cstrong\u003e$486.5 million\u003c\/strong\u003e\n\u003c\/li\u003e\n \u003cli\u003eCapital expenditures in 2023: \u003cstrong\u003e$159.8 million\u003c\/strong\u003e\n\u003c\/li\u003e\n \u003cli\u003eCash and cash equivalents at December 31, 2023: \u003cstrong\u003e$1.23 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFor academic work, the key activities section can be written around five numbers: \u003cstrong\u003e$486.5 million\u003c\/strong\u003e R\u0026amp;D, \u003cstrong\u003e$159.8 million\u003c\/strong\u003e capex, \u003cstrong\u003e$3.62 billion\u003c\/strong\u003e revenue, \u003cstrong\u003e$2.30 billion\u003c\/strong\u003e U.S. revenue, and \u003cstrong\u003e$1.32 billion\u003c\/strong\u003e non-U.S. revenue.\u003c\/p\u003e\n\u003ch2\u003eDexCom, Inc. - Canvas Business Model: Key Resources\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003e3.5 million\u003c\/strong\u003e active users\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e$2.4 billion\u003c\/strong\u003e in cash and cash equivalents\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey resource\u003c\/td\u003e\n\u003ctd\u003eReal-life number or amount\u003c\/td\u003e\n\u003ctd\u003eBusiness model role\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG7 15-Day CGM platform\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e15\u003c\/strong\u003e days\u003c\/td\u003e\n\u003ctd\u003eContinuous glucose monitoring platform with longer wear time\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStelo biosensor and app\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e14\u003c\/strong\u003e days\u003c\/td\u003e\n\u003ctd\u003eOver-the-counter glucose biosensor system and app-based user interface\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive users\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eInstalled user base supporting recurring sensor demand\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and cash equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.4 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLiquidity for product development, manufacturing, and commercial expansion\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e15\u003c\/strong\u003e-day wear on the G7 platform raises the value of the installed sensor ecosystem because fewer sensor changes can improve convenience.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e14\u003c\/strong\u003e-day wear on Stelo supports a direct-to-consumer style product model tied to app use and recurring biosensor replacements.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e3.5 million\u003c\/strong\u003e active users show the scale of the recurring customer base behind sensor sales.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e$2.4 billion\u003c\/strong\u003e in cash gives DexCom room to fund operations without immediate financing pressure.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe G7 15-Day CGM platform is a core physical and digital asset because it combines the sensor, transmitter, software, and data flow that support recurring use. In business model terms, this resource matters because it drives repeat purchases, software engagement, and clinical adoption across insulin users and non-insulin users.\u003c\/p\u003e\n\n\u003cp\u003eThe Stelo biosensor and app add a second resource layer. The product expands DexCom's reach beyond prescription-only users and turns app software into part of the value chain. The \u003cstrong\u003e14\u003c\/strong\u003e-day sensor cycle is important because wear duration directly affects replacement frequency, which shapes recurring revenue potential.\u003c\/p\u003e\n\n\u003cp\u003eThe \u003cstrong\u003e3.5 million\u003c\/strong\u003e active users resource matters because it reflects scale. A large installed base usually lowers customer acquisition pressure per user over time and increases the value of connected data, support, and platform familiarity.\u003c\/p\u003e\n\n\u003cp\u003eThe \u003cstrong\u003e$2.4 billion\u003c\/strong\u003e cash position is a financial resource, not a product resource. It supports research and development, sales and marketing, manufacturing build-out, and working capital needs. In plain English, cash is the money a company can use now, while cash flow is the money moving in and out of the business over time.\u003c\/p\u003e\n\n\u003cp\u003eExpanded manufacturing capacity is a strategic resource because CGM businesses depend on reliable output, quality control, and supply continuity. If capacity rises, DexCom can meet higher demand for sensors and biosensors without the same risk of shortages or bottlenecks.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eProduct resources: G7 15-Day CGM platform, Stelo biosensor, app software\u003c\/li\u003e\n \u003cli\u003eCustomer resources: \u003cstrong\u003e3.5 million\u003c\/strong\u003e active users\u003c\/li\u003e\n \u003cli\u003eFinancial resources: \u003cstrong\u003e$2.4 billion\u003c\/strong\u003e cash and cash equivalents\u003c\/li\u003e\n \u003cli\u003eOperational resources: expanded manufacturing capacity\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIn a Business Model Canvas, these resources support value creation, customer retention, and scale. The combination of a longer-wear CGM platform, an app-linked biosensor, a multi-million-user base, and strong liquidity is what allows DexCom to keep developing, producing, and selling glucose monitoring products at scale.\u003c\/p\u003e\u003ch2\u003eDexCom, Inc. - Canvas Business Model: Value Propositions\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eDexCom, Inc.\u003c\/strong\u003e offers a longer-wear continuous glucose monitoring system, real-time glucose data every \u003cstrong\u003e5 minutes\u003c\/strong\u003e, and products for both insulin users and adults with non-insulin metabolic health needs. Its value proposition centers on reducing fingerstick dependence, improving day-to-day glucose visibility, and making access simpler through pharmacy and insurance workflows.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eValue Proposition Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eReal-Life Number or Product Detail\u003c\/strong\u003e\u003c\/td\u003e\n \u003ctd\u003e\u003cstrong\u003eBusiness Impact\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLonger-wear CGM\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e15 days\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFewer sensor changes and lower interruption in monitoring\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlucose data frequency\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eEvery 5 minutes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eContinuous visibility into glucose changes across the day and night\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWear duration of earlier flagship CGM\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10 days\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eShows the move from shorter wear to longer wear\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-insulin metabolic health product\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e18 years and older\u003c\/strong\u003e, not using insulin\u003c\/td\u003e\n \u003ctd\u003eExpands the addressable user base beyond insulin-treated diabetes\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrescription status for over-the-counter CGM\u003c\/td\u003e\n \u003ctd\u003e\u003cstrong\u003eNo prescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReduces access friction for eligible consumers\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical insulin-pump integration\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1 hour\u003c\/strong\u003e warm-up for Dexcom G7\u003c\/td\u003e\n \u003ctd\u003eShortens time to usable data after sensor start\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eLonger-wear 15-day CGM\u003c\/strong\u003e is a direct product value because it reduces how often you need to replace a sensor. A \u003cstrong\u003e15-day\u003c\/strong\u003e wear period means up to \u003cstrong\u003e24\u003c\/strong\u003e sensor periods per year instead of \u003cstrong\u003e36.5\u003c\/strong\u003e sensor periods for a \u003cstrong\u003e10-day\u003c\/strong\u003e sensor, before any grace periods or early replacements. That lower replacement frequency matters for convenience, adherence, and supply handling. For academic work, this is a clear example of how product design affects user retention and operating simplicity.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e15 days\u003c\/strong\u003e of wear per sensor\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e10 days\u003c\/strong\u003e for the earlier flagship CGM wear period\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e1 hour\u003c\/strong\u003e warm-up for Dexcom G7\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e5-minute\u003c\/strong\u003e glucose readings\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eReal-time glucose monitoring\u003c\/strong\u003e is the core functional value. DexCom systems provide glucose readings every \u003cstrong\u003e5 minutes\u003c\/strong\u003e, which equals \u003cstrong\u003e288\u003c\/strong\u003e readings per day. That matters because glucose can change quickly after meals, exercise, sleep, or insulin use. Real-time data can support faster action than a single daily fingerstick. For students writing about the business model, this is the clearest link between product capability and customer value: higher-frequency data increases usefulness, which can support repeat usage and system loyalty.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e288\u003c\/strong\u003e glucose data points per day at \u003cstrong\u003e5-minute\u003c\/strong\u003e intervals\u003c\/li\u003e\n \u003cli\u003eContinuous tracking across \u003cstrong\u003e24\u003c\/strong\u003e hours\u003c\/li\u003e\n \u003cli\u003eDesigned for users who need visibility into highs and lows\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eNon-insulin metabolic health tracking\u003c\/strong\u003e extends the value proposition beyond diabetes treatment. DexCom launched an over-the-counter CGM under the name Stelo for adults \u003cstrong\u003e18 years and older\u003c\/strong\u003e who do not use insulin. That matters because the product is not limited to prescription-only diabetes care. It targets people who want to observe how food, sleep, and exercise affect glucose patterns. From a business model angle, this opens a separate market segment with different buying behavior and a simpler access path.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdults \u003cstrong\u003e18 years and older\u003c\/strong\u003e\n\u003c\/li\u003e\n \u003cli\u003e\u003cstrong\u003eNo insulin use\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNo prescription\u003c\/strong\u003e required\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eSegment\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eAccess Model\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003ePrimary Need\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInsulin users\u003c\/td\u003e\n\u003ctd\u003ePrescription and payer-based access\u003c\/td\u003e\n\u003ctd\u003eGlucose monitoring for treatment decisions\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-insulin adults\u003c\/td\u003e\n\u003ctd\u003eOver-the-counter access\u003c\/td\u003e\n\u003ctd\u003eBehavior tracking and metabolic awareness\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eSimplified ordering and insurance verification\u003c\/strong\u003e lowers friction in getting started and staying on the product. For a medical device business, access is part of the value proposition, not just a back-office process. When ordering is simpler and coverage checks are faster, the user faces fewer delays between diagnosis, prescription, and first use. This is especially important in a category where adherence and continuity depend on uninterrupted supply delivery. In academic analysis, this is a useful example of how service design supports product adoption.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrescription-based CGM users\u003c\/li\u003e\n\u003cli\u003eInsurance verification workflow\u003c\/li\u003e\n\u003cli\u003ePharmacy-channel access\u003c\/li\u003e\n\u003cli\u003eLower administrative burden for users and clinics\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eIntegrated insulin dosing support\u003c\/strong\u003e is a high-value proposition for people on intensive insulin therapy and for the clinicians managing them. DexCom CGM data can be used with insulin delivery systems and diabetes management workflows that rely on current glucose readings. The value is not only visibility; it is actionability. In plain English, the system helps users turn data into dosing decisions faster than periodic fingerstick checks. That matters because insulin treatment often depends on near-real-time data, especially around meals and corrections.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e5-minute\u003c\/strong\u003e data updates for dosing decisions\u003c\/li\u003e\n \u003cli\u003eUse with insulin therapy workflows\u003c\/li\u003e\n\u003cli\u003eClinical support for high- and low-glucose detection\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eDexCom's value proposition is strongest where monitoring frequency, wear duration, and access simplicity overlap. The numbers that define it are the \u003cstrong\u003e15-day\u003c\/strong\u003e wear period, \u003cstrong\u003e5-minute\u003c\/strong\u003e readings, \u003cstrong\u003e18+\u003c\/strong\u003e OTC eligibility for non-insulin use, and \u003cstrong\u003e1-hour\u003c\/strong\u003e warm-up on Dexcom G7. These are the operational features that shape customer choice, channel strategy, and product differentiation.\u003c\/p\u003e\u003ch2\u003eDexCom, Inc. - Canvas Business Model: Customer Relationships\u003c\/h2\u003e\n\n\u003cp\u003eDexCom's customer relationships are built around \u003cstrong\u003eself-service digital access\u003c\/strong\u003e, \u003cstrong\u003econtinuous app-based monitoring\u003c\/strong\u003e, and \u003cstrong\u003edevice-to-device integration\u003c\/strong\u003e. The relationship is designed to keep users engaged every day, because glucose data updates every \u003cstrong\u003e5 minutes\u003c\/strong\u003e and the newest G7 sensor is built for \u003cstrong\u003e10-day\u003c\/strong\u003e wear.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eRelationship channel\u003c\/td\u003e\n\u003ctd\u003eCore customer need\u003c\/td\u003e\n\u003ctd\u003eRelevant number or feature\u003c\/td\u003e\n\u003ctd\u003eWhy it matters\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMy Dexcom Account\u003c\/td\u003e\n\u003ctd\u003eSelf-service account and order management\u003c\/td\u003e\n \u003ctd\u003eDigital portal access\u003c\/td\u003e\n\u003ctd\u003eReduces friction for account tasks and keeps users inside the company's own digital system\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMobile app-based monitoring\u003c\/td\u003e\n\u003ctd\u003eReal-time glucose visibility\u003c\/td\u003e\n\u003ctd\u003eGlucose updates every \u003cstrong\u003e5 minutes\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003ctd\u003eCreates a daily usage habit and makes the product hard to replace\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner app integrations\u003c\/td\u003e\n\u003ctd\u003eData sharing across devices and platforms\u003c\/td\u003e\n \u003ctd\u003eCompatible third-party apps and connected devices\u003c\/td\u003e\n \u003ctd\u003eExtends reach beyond the company's own app and supports ecosystem retention\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG6 to G7 upgrade path\u003c\/td\u003e\n\u003ctd\u003eLower switching friction for existing users\u003c\/td\u003e\n \u003ctd\u003eG7 sensor wear period: \u003cstrong\u003e10 days\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003ctd\u003eSupports retention by making upgrades simple instead of forcing a new routine\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect digital customer engagement\u003c\/td\u003e\n\u003ctd\u003eEducation, onboarding, and support\u003c\/td\u003e\n\u003ctd\u003eApp, portal, and digital communications\u003c\/td\u003e\n\u003ctd\u003eImproves adoption, reduces support friction, and keeps users linked to the brand\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eMy Dexcom Account\u003c\/strong\u003e works as the company's self-service layer. It gives users a digital place to manage account-related activity without relying only on phone-based support. In customer relationship terms, this matters because a self-service portal lowers service costs per user and reduces delays in routine tasks. For academic analysis, you can treat it as a retention tool: once users create an account and keep using it for access and management, switching away becomes less convenient.\u003c\/p\u003e\n\n\u003cp\u003eThe portal also fits the company's recurring-revenue model because glucose monitoring is not a one-time purchase experience. It is a repeat-use relationship tied to sensors, software, and replacement cycles. The more a user depends on the portal for account control, the more the relationship shifts from a single product sale to an ongoing service connection.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eMobile app-based monitoring\u003c\/strong\u003e is the center of day-to-day customer engagement. Dexcom's CGM system sends glucose data every \u003cstrong\u003e5 minutes\u003c\/strong\u003e, which means the user is interacting with the system many times per day. That frequency is important because it builds routine. In business model terms, high-frequency usage increases product stickiness, which means users are less likely to stop using it once they rely on it for daily decisions.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eReal-time data delivery supports frequent app use.\u003c\/li\u003e\n \u003cli\u003eAlert-based monitoring increases trust in the system.\u003c\/li\u003e\n \u003cli\u003eDaily engagement creates repeated contact with the brand.\u003c\/li\u003e\n \u003cli\u003eRepeated contact improves the chances of renewal and upgrade.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003ePartner app integrations\u003c\/strong\u003e expand the relationship beyond the company's own app. This matters because customers do not live in a single digital system. Many want glucose data to connect with phones, watches, wellness tools, or health platforms. By linking into a broader ecosystem, the company makes its data easier to use and harder to abandon. That lowers churn risk because customers are not just buying a sensor; they are building a connected workflow around it.\u003c\/p\u003e\n\n\u003cp\u003eFor academic writing, partner integrations are a good example of ecosystem strategy. The company keeps the customer relationship alive through third-party compatibility rather than trying to own every touchpoint itself. That is a practical way to improve convenience without forcing users into a closed system.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOngoing upgrade path from G6 to G7\u003c\/strong\u003e is a retention mechanism. The G7 sensor uses a \u003cstrong\u003e10-day\u003c\/strong\u003e wear period, which helps create continuity for existing users moving from one generation to the next. When a company makes upgrading simple, it reduces the risk that customers will pause, compare alternatives, or abandon the category. In customer relationship terms, smoother upgrades protect lifetime value, which is the total revenue a customer can generate over time.\u003c\/p\u003e\n\n\u003cp\u003eThat upgrade path also matters because it turns product replacement into relationship renewal. Instead of losing the customer at the end of one device cycle, the company has a chance to keep them in the same app, the same account structure, and the same digital support flow. That is a strong academic example of how product development supports customer retention.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDirect digital customer engagement\u003c\/strong\u003e combines onboarding, education, alerts, and support inside a digital-first model. This is not just communication; it is relationship management. The company uses direct channels to explain setup, encourage use, and keep users active in the system. In a high-touch health technology category, that matters because user confidence affects adherence. If customers understand the product and trust the alerts, they are more likely to stay with it.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eDigital onboarding reduces early drop-off.\u003c\/li\u003e\n \u003cli\u003eEducation improves correct use of the sensor and app.\u003c\/li\u003e\n \u003cli\u003eOngoing alerts keep the user connected to the system.\u003c\/li\u003e\n \u003cli\u003eSupport through digital channels can lower service friction.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomer relationship element\u003c\/td\u003e\n\u003ctd\u003eNumber or metric\u003c\/td\u003e\n\u003ctd\u003eBusiness effect\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlucose reading frequency\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5 minutes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eHigh engagement frequency\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG7 wear period\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10 days\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRecurring replacement cycle and retention opportunity\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital account structure\u003c\/td\u003e\n\u003ctd\u003eMy Dexcom Account\u003c\/td\u003e\n\u003ctd\u003eSelf-service relationship management\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntegration model\u003c\/td\u003e\n\u003ctd\u003eCompatible partner apps and connected devices\u003c\/td\u003e\n \u003ctd\u003eBroader ecosystem use and lower switching risk\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eIn Business Model Canvas terms, this customer relationship setup is a mix of \u003cstrong\u003eself-service\u003c\/strong\u003e, \u003cstrong\u003eautomated service\u003c\/strong\u003e, and \u003cstrong\u003ecommunity or ecosystem-based support\u003c\/strong\u003e. The company keeps the customer close through frequent data updates, simple digital management, and upgrade continuity. That makes the relationship less dependent on one-time sales and more dependent on repeated digital engagement.\u003c\/p\u003e\u003ch2\u003eDexCom, Inc. - Canvas Business Model: Channels\u003c\/h2\u003e\n\n\u003cp\u003eDexCom, Inc. reaches users through \u003cstrong\u003emobile apps\u003c\/strong\u003e, a \u003cstrong\u003eMy Dexcom Account\u003c\/strong\u003e portal, \u003cstrong\u003epharmacy and reimbursement\u003c\/strong\u003e pathways, and partner distribution through the \u003cstrong\u003eOura\u003c\/strong\u003e app ecosystem and the \u003cstrong\u003eSignos\u003c\/strong\u003e platform. The channel mix matters because DexCom sells a recurring, sensor-based product, so the route to the customer affects adoption, refill frequency, and access.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eFunction\u003c\/th\u003e\n\u003cth\u003eBusiness impact\u003c\/th\u003e\n\u003cth\u003eReal-life channel detail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDexcom mobile apps\u003c\/td\u003e\n\u003ctd\u003eDisplay glucose data, alerts, and sharing functions\u003c\/td\u003e\n \u003ctd\u003eSupports user engagement and day-to-day product use\u003c\/td\u003e\n \u003ctd\u003eApp-based viewing and sharing for continuous glucose monitoring\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMy Dexcom Account portal\u003c\/td\u003e\n\u003ctd\u003eAccount setup, ordering support, and account management\u003c\/td\u003e\n \u003ctd\u003eReduces friction in onboarding and fulfillment\u003c\/td\u003e\n \u003ctd\u003eWeb-based customer account channel\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacy and reimbursement channels\u003c\/td\u003e\n\u003ctd\u003ePrescription fulfillment and payer coverage\u003c\/td\u003e\n \u003ctd\u003eDrives scale through insurance access and retail pharmacy distribution\u003c\/td\u003e\n \u003ctd\u003ePrescription-based model with reimbursement dependence\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOura app ecosystem\u003c\/td\u003e\n\u003ctd\u003eIntegrates glucose data into a third-party health app environment\u003c\/td\u003e\n \u003ctd\u003eExpands awareness and embedded use cases\u003c\/td\u003e\n \u003ctd\u003ePartner app distribution channel\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSignos platform distribution\u003c\/td\u003e\n\u003ctd\u003eUses DexCom data in a metabolic health platform\u003c\/td\u003e\n \u003ctd\u003eReaches consumers through a guided digital health service\u003c\/td\u003e\n \u003ctd\u003ePartner-led consumer acquisition channel\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eDexcom mobile apps\u003c\/strong\u003e are the most visible customer channel because they turn sensor output into daily glucose visibility. The channel is not just a display layer. It is part of the product experience itself, since continuous glucose monitoring depends on frequent app use for readings, alerts, and data review. That makes the app a retention tool as well as a delivery channel. For academic analysis, this matters because it shows that DexCom is not only selling hardware. It is selling a recurring digital-service experience around each sensor cycle.\u003c\/p\u003e\n\n\u003cp\u003eThe app channel also supports remote sharing, which is important for caregivers and clinicians. In continuous glucose monitoring, data sharing can influence adherence and clinical follow-up. That raises the value of the app beyond the user alone. The channel therefore supports both consumer use and clinical utility, which helps DexCom stay embedded in the user's daily routine.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChannel role: daily data access\u003c\/li\u003e\n\u003cli\u003eChannel role: alert delivery\u003c\/li\u003e\n\u003cli\u003eChannel role: caregiver sharing\u003c\/li\u003e\n\u003cli\u003eChannel role: engagement during each sensor wear cycle\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eMy Dexcom Account\u003c\/strong\u003e is the ownership and service channel. It helps users manage account details, product ordering, and support-related actions. In business model terms, this channel lowers friction between interest and repeat use. That is important in a prescription and refill model because every extra step can reduce conversion. The portal also supports repeat purchasing behavior, which matters in a product category with recurring replacement demand.\u003c\/p\u003e\n\n\u003cp\u003eThis channel is especially relevant where customers need a structured path from prescription to shipment. In a business where the sensor lifecycle is measured in days rather than years, a clean account and order process matters. A 10-day sensor wear period means the customer comes back to the company repeatedly, so the account channel affects continuity of demand.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChannel role: account creation and management\u003c\/li\u003e\n \u003cli\u003eChannel role: ordering support\u003c\/li\u003e\n\u003cli\u003eChannel role: service and replenishment coordination\u003c\/li\u003e\n \u003cli\u003eChannel role: repeat-use continuity\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003ePharmacy and reimbursement channels\u003c\/strong\u003e are central to DexCom's scale. The company's model depends on prescription access and payer reimbursement because most users do not buy continuous glucose monitoring systems as ordinary retail items. The pharmacy channel shortens the time between prescription and product pickup or shipment, while reimbursement determines whether coverage lowers out-of-pocket cost.\u003c\/p\u003e\n\n\u003cp\u003eFor analysis, this channel is important because reimbursement drives adoption. If coverage expands, the addressable market grows faster. If coverage tightens, growth slows. That means the channel is not just a distribution route. It is a gatekeeper for revenue conversion. In practical terms, pharmacy access can be more efficient than durable medical equipment-style handling because it can simplify fulfillment and improve refill flow.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChannel role: prescription fulfillment\u003c\/li\u003e\n\u003cli\u003eChannel role: payer access\u003c\/li\u003e\n\u003cli\u003eChannel role: lower consumer friction when coverage is available\u003c\/li\u003e\n \u003cli\u003eChannel role: recurring refill behavior\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eDexCom's channel economics are tied to recurring usage. A \u003cstrong\u003e10-day\u003c\/strong\u003e sensor cycle means a user may need \u003cstrong\u003e36\u003c\/strong\u003e sensors in a \u003cstrong\u003e360-day\u003c\/strong\u003e period if use is continuous. That is why pharmacy and reimbursement access matter so much. The channel is built around repeated fulfillment rather than one-time device sale economics.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOura app ecosystem\u003c\/strong\u003e functions as a partner distribution channel. DexCom's glucose data can be surfaced inside a third-party wellness environment, which gives the company reach beyond its own app users. This matters because partner channels can expose DexCom data to consumers who may not begin with a diabetes-focused workflow. That broadens discovery and can support interest from users tracking sleep, activity, and metabolic health in one place.\u003c\/p\u003e\n\n\u003cp\u003eThis channel is strategically useful because it places DexCom inside a wider consumer health app with an existing user base. In business model terms, that can reduce customer acquisition friction. It also positions DexCom as part of a broader digital health stack rather than a stand-alone medical device.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChannel role: third-party app integration\u003c\/li\u003e\n \u003cli\u003eChannel role: consumer discovery outside DexCom-owned apps\u003c\/li\u003e\n \u003cli\u003eChannel role: broader metabolic health positioning\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eSignos platform distribution\u003c\/strong\u003e is another partner channel that embeds DexCom data in a guided consumer platform. This matters because a platform model can combine device data, coaching, and behavior support in one customer journey. For DexCom, the channel extends reach into users who enter through a metabolic health service instead of a direct sensor purchase.\u003c\/p\u003e\n\n\u003cp\u003eThat type of channel is important in academic analysis because it shows multi-sided distribution. DexCom is not only selling to patients and payers. It is also enabling partner platforms that package its data inside a consumer service. This can improve accessibility, but it also means DexCom partly depends on partner experience design for customer conversion and retention.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eCustomer entry point\u003c\/th\u003e\n\u003cth\u003eValue delivered\u003c\/th\u003e\n\u003cth\u003eStrategic risk\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDexcom mobile apps\u003c\/td\u003e\n\u003ctd\u003eDirect app download and use\u003c\/td\u003e\n\u003ctd\u003eGlucose readings, alerts, and sharing\u003c\/td\u003e\n\u003ctd\u003eLow engagement if alerts and usability are weak\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMy Dexcom Account\u003c\/td\u003e\n\u003ctd\u003eWeb portal login and order management\u003c\/td\u003e\n\u003ctd\u003eAccount support and replenishment\u003c\/td\u003e\n\u003ctd\u003eOrder friction can reduce repeat conversion\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacy and reimbursement\u003c\/td\u003e\n\u003ctd\u003ePrescription and coverage approval\u003c\/td\u003e\n\u003ctd\u003eLower access barriers where covered\u003c\/td\u003e\n\u003ctd\u003ePayer policy changes can slow adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOura app ecosystem\u003c\/td\u003e\n\u003ctd\u003ePartner app integration\u003c\/td\u003e\n\u003ctd\u003eMetabolic health visibility inside a broader wellness app\u003c\/td\u003e\n \u003ctd\u003eDependence on partner app adoption and integration quality\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSignos platform distribution\u003c\/td\u003e\n\u003ctd\u003ePartner platform onboarding\u003c\/td\u003e\n\u003ctd\u003eGuided consumer experience around DexCom data\u003c\/td\u003e\n \u003ctd\u003ePartner-led customer experience can shape conversion\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe channel structure fits a recurring-use model. A sensor system with a \u003cstrong\u003e10-day\u003c\/strong\u003e wear period creates repeated touchpoints through apps, portals, refill pathways, and partners. That makes channels a major driver of revenue continuity, not just sales access. The more efficiently DexCom converts prescriptions into active users and repeat fills, the stronger the channel economics become.\u003c\/p\u003e\n\u003ch2\u003eDexCom, Inc. - Canvas Business Model: Customer Segments\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eDexCom, Inc. sells continuous glucose monitoring systems to people with diabetes, especially adults with type 2 diabetes and people who use insulin, and it is expanding into non-insulin users, metabolic health consumers, payers, and providers.\u003c\/strong\u003e The customer base is large because diabetes is widespread: the International Diabetes Federation estimated \u003cstrong\u003e537 million\u003c\/strong\u003e adults aged 20 to 79 were living with diabetes in 2021, and the number was projected to rise to \u003cstrong\u003e643 million\u003c\/strong\u003e by 2030 and \u003cstrong\u003e783 million\u003c\/strong\u003e by 2045.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eCustomer segment\u003c\/th\u003e\n\u003cth\u003eReal-life scale\u003c\/th\u003e\n\u003cth\u003eWhat the segment needs\u003c\/th\u003e\n\u003cth\u003eWhy it matters to DexCom, Inc.\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeople with diabetes\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e537 million\u003c\/strong\u003e adults worldwide in 2021\u003c\/td\u003e\n \u003ctd\u003eReal-time glucose data, alerts, trend tracking, and fewer fingersticks\u003c\/td\u003e\n \u003ctd\u003eLargest addressable clinical market for continuous glucose monitoring\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdults with type 2 diabetes\u003c\/td\u003e\n\u003ctd\u003eLargest diabetes subtype globally\u003c\/td\u003e\n\u003ctd\u003eSimple, low-friction monitoring that supports medication and diet decisions\u003c\/td\u003e\n \u003ctd\u003eMain growth pool beyond type 1 diabetes and insulin-dependent users\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-insulin users\u003c\/td\u003e\n\u003ctd\u003eLarge and underpenetrated segment\u003c\/td\u003e\n\u003ctd\u003eBehavior feedback, visibility into food and activity effects, easier adoption\u003c\/td\u003e\n \u003ctd\u003eExpands volume well beyond traditional intensive insulin therapy\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetabolic health consumers\u003c\/td\u003e\n\u003ctd\u003eIncludes people without diabetes who track glucose for wellness and weight-related goals\u003c\/td\u003e\n \u003ctd\u003ePersonalized metabolic feedback and habit change signals\u003c\/td\u003e\n \u003ctd\u003eCreates a consumer channel outside disease management\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers and providers\u003c\/td\u003e\n\u003ctd\u003eCommercial insurers, public programs, health systems, physicians, and clinics\u003c\/td\u003e\n \u003ctd\u003eEvidence of outcomes, cost control, adherence, and workflow fit\u003c\/td\u003e\n \u003ctd\u003eControls access, reimbursement, and prescribing volume\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003ePeople with diabetes\u003c\/strong\u003e are the core customer group. This segment includes type 1 diabetes, type 2 diabetes, gestational diabetes in some care settings, and insulin-treated patients who need frequent glucose visibility. The business logic is simple: diabetes management depends on knowing glucose levels, trends, and hypoglycemia risk. Continuous glucose monitoring supports that need better than episodic testing because it gives data throughout the day and night. This segment matters because it is the clinical foundation of the company's business model and the strongest use case for payer reimbursement and physician recommendation.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAdults with type 2 diabetes\u003c\/strong\u003e are a major growth segment because they represent a much larger population than type 1 diabetes. Global diabetes prevalence of \u003cstrong\u003e537 million\u003c\/strong\u003e adults in 2021 means the type 2 pool is large enough to support broad adoption if pricing, reimbursement, and ease of use continue to improve. For this segment, the main customer need is not only glucose measurement but also simple decision support. People with type 2 diabetes often want to understand how meals, movement, and medication affect glucose without having to use complex tools. That makes this segment important for scale, recurring sensor sales, and long-term revenue growth.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eNon-insulin users\u003c\/strong\u003e are strategically important because they widen the market beyond patients on intensive insulin therapy. This group includes adults with type 2 diabetes who manage their condition with oral drugs, GLP-1 therapies, diet, exercise, or a mix of treatments. They may not need the same level of glucose management every day as insulin users, but they still benefit from pattern recognition and behavior feedback. For DexCom, Inc., this segment matters because it can increase the installed base of users and lower dependence on a narrower subset of high-acuity patients. It also raises the importance of insurer coverage and clinician support, because adoption in this group often depends on whether the product is paid for and recommended in routine care.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eLarge potential user base beyond insulin-treated patients\u003c\/li\u003e\n \u003cli\u003eLower clinical intensity, but still meaningful need for glucose visibility\u003c\/li\u003e\n \u003cli\u003eHigh sensitivity to out-of-pocket cost and reimbursement rules\u003c\/li\u003e\n \u003cli\u003eImportant for recurring sensor demand if adoption becomes standard in primary care\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eMetabolic health consumers\u003c\/strong\u003e are people using glucose data to support wellness, nutrition, exercise, or weight management goals rather than traditional diabetes treatment. This segment is smaller and more consumer-driven than the medical segments, but it is strategically useful because it broadens the company's brand reach and creates a new demand source outside payer-heavy channels. The customer need here is individualized feedback. Users want to see how food choices, sleep, and physical activity affect glucose in real time. That makes the segment valuable for direct-to-consumer education, app engagement, and future cross-sell into clinical use if a user later develops prediabetes or diabetes.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePayers and providers\u003c\/strong\u003e are not the end users of the sensor in the same way a patient is, but they are a separate customer segment because they control access and adoption. Payers include commercial insurers, government programs, and pharmacy benefit managers. Providers include endocrinologists, primary care physicians, diabetes educators, clinics, and health systems. Their main need is evidence that continuous glucose monitoring improves outcomes, reduces acute events, and fits clinical workflows. This segment matters because it influences reimbursement coverage, prescribing patterns, and patient retention. Without payer support and provider confidence, even a strong consumer product faces slower adoption.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003ePrimary decision maker\u003c\/th\u003e\n\u003cth\u003ePrimary buying trigger\u003c\/th\u003e\n\u003cth\u003eCommercial impact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeople with diabetes\u003c\/td\u003e\n\u003ctd\u003ePatient, clinician, insurer\u003c\/td\u003e\n\u003ctd\u003eNeed for glucose visibility and better control\u003c\/td\u003e\n \u003ctd\u003eRecurring sensor use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdults with type 2 diabetes\u003c\/td\u003e\n\u003ctd\u003ePatient and physician\u003c\/td\u003e\n\u003ctd\u003eMedication management and easier self-care\u003c\/td\u003e\n \u003ctd\u003eLargest expansion pool\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-insulin users\u003c\/td\u003e\n\u003ctd\u003ePatient, payer, physician\u003c\/td\u003e\n\u003ctd\u003eCoverage and lifestyle support\u003c\/td\u003e\n\u003ctd\u003eCategory expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetabolic health consumers\u003c\/td\u003e\n\u003ctd\u003eConsumer\u003c\/td\u003e\n\u003ctd\u003eWellness, weight, and habit tracking\u003c\/td\u003e\n\u003ctd\u003eDirect-to-consumer growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers and providers\u003c\/td\u003e\n\u003ctd\u003ePlan, health system, clinic\u003c\/td\u003e\n\u003ctd\u003eOutcomes, cost control, workflow fit\u003c\/td\u003e\n\u003ctd\u003eAccess and reimbursement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe segment mix is important because it affects how DexCom, Inc. sells, prices, and scales. Clinical diabetes users create the core recurring revenue base. Type 2 and non-insulin users expand the addressable market. Metabolic health consumers add a consumer layer. Payers and providers determine how fast each segment can grow through coverage and prescribing behavior. In practice, this means the customer base is not one market but several markets with different purchase logic, reimbursement rules, and usage patterns.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eClinical users\u003c\/strong\u003e: people with diabetes who need daily glucose management\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003eHigh-volume growth users\u003c\/strong\u003e: adults with type 2 diabetes\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003eCoverage-sensitive users\u003c\/strong\u003e: non-insulin users\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003eConsumer-led users\u003c\/strong\u003e: metabolic health consumers\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003eAccess gatekeepers\u003c\/strong\u003e: payers and providers\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFor academic work, this customer segmentation shows that the business model depends on both medical necessity and reimbursement structure. The same product can serve a patient who needs clinical care, a consumer who wants wellness feedback, and a payer that wants lower long-term costs. That mix makes the segment design central to understanding demand, growth, and adoption risk.\u003c\/p\u003e\u003ch2\u003eDexCom, Inc. - Canvas Business Model: Cost Structure\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003e2024 revenue was $4.03 billion.\u003c\/strong\u003e The cost structure was driven mainly by manufacturing, research and development, and sales and marketing, with additional pressure from logistics, regulatory work, and legal spending.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eGross profit was $2.49 billion.\u003c\/strong\u003e That implies a gross margin of \u003cstrong\u003e61.8%\u003c\/strong\u003e and shows that production and supply chain execution are central to cost control.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost structure item\u003c\/td\u003e\n\u003ctd\u003eReal-life number\u003c\/td\u003e\n\u003ctd\u003ePeriod\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.03 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross profit\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.49 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e61.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eManufacturing and capacity expansion\u003c\/strong\u003e are the largest fixed-cost drivers in the model. DexCom has to fund sensor production, assembly, quality control, and plant expansion before the related revenue is collected. In a business with continuous device demand, capacity additions matter because underused facilities raise unit costs, while constrained capacity can limit growth and hurt service levels.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eHigh-volume production requires clean-room operations, test systems, and quality inspection.\u003c\/li\u003e\n \u003cli\u003eCapacity expansion adds depreciation, equipment, and labor costs before output is fully ramped.\u003c\/li\u003e\n \u003cli\u003eManufacturing yield has a direct effect on cost of revenue because scrap and rework raise unit cost.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eR\u0026amp;D and software development\u003c\/strong\u003e are structural costs, not optional spending. DexCom must keep funding sensor accuracy, connectivity, app performance, cloud infrastructure, and interoperability work. For a medical device company, R\u0026amp;D is also tied to product life cycle protection because product refreshes and software updates are needed to preserve clinical relevance.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eR\u0026amp;D spending supports new sensor generations, algorithms, and mobile software.\u003c\/li\u003e\n \u003cli\u003eSoftware costs include engineering, validation, cybersecurity, and maintenance.\u003c\/li\u003e\n \u003cli\u003eThese costs matter because they support future revenue, but they also reduce near-term operating profit.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eLogistics and freight\u003c\/strong\u003e matter because DexCom ships a physical product with recurring replacement demand. Freight costs rise when the company serves many geographies, when air transport is needed, or when inventory has to be repositioned quickly. In a subscription-like model with continuous sensor replenishment, shipping expense is not a one-time cost; it recurs with each customer cycle.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eFreight affects cost of sales when products move from plants to distribution points and customers.\u003c\/li\u003e\n \u003cli\u003eInternational shipping adds customs, handling, and inventory transfer costs.\u003c\/li\u003e\n \u003cli\u003eDelivery reliability matters because late shipments can disrupt patient use and increase support costs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRegulatory and recall costs\u003c\/strong\u003e are part of operating in a medical device market. These costs include submissions, clinical documentation, quality systems, post-market surveillance, and corrective actions if product issues arise. They are important because every product change must stay within regulatory rules, and any field action can create direct expense plus reputational damage.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory and quality cost category\u003c\/td\u003e\n\u003ctd\u003eFinancial effect\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory submissions\u003c\/td\u003e\n\u003ctd\u003eInternal labor, testing, and documentation expense\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePost-market surveillance\u003c\/td\u003e\n\u003ctd\u003eMonitoring, complaint handling, and data analysis cost\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecall or field action\u003c\/td\u003e\n\u003ctd\u003eReplacement, logistics, communication, and quality remediation cost\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eLegal and litigation expenses\u003c\/strong\u003e can be meaningful in a company with valuable intellectual property and a regulated product set. Legal spending covers patent defense, commercial disputes, employment matters, contract review, and compliance support. These costs affect operating margins because they do not directly create revenue, but they can protect market position and product rights.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003ePatent disputes can be expensive because they require outside counsel and technical experts.\u003c\/li\u003e\n \u003cli\u003eContract and compliance work rises as the company expands partnerships and geography.\u003c\/li\u003e\n \u003cli\u003eLitigation reserves, if recorded, can create volatility in quarterly earnings.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost bucket\u003c\/td\u003e\n\u003ctd\u003eWhy it matters for the business model\u003c\/td\u003e\n\u003ctd\u003eFinancial impact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing and capacity expansion\u003c\/td\u003e\n\u003ctd\u003eSupports product supply and growth\u003c\/td\u003e\n\u003ctd\u003eRaises fixed costs and depreciation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D and software development\u003c\/td\u003e\n\u003ctd\u003eProtects product leadership and future sales\u003c\/td\u003e\n \u003ctd\u003eReduces current operating profit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics and freight\u003c\/td\u003e\n\u003ctd\u003eMoves product to patients and distributors\u003c\/td\u003e\n \u003ctd\u003eRaises cost of sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory and recall costs\u003c\/td\u003e\n\u003ctd\u003eKeeps products approved and marketable\u003c\/td\u003e\n\u003ctd\u003eCan create sudden expense spikes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegal and litigation expenses\u003c\/td\u003e\n\u003ctd\u003eProtects IP and limits compliance risk\u003c\/td\u003e\n\u003ctd\u003eCan pressure margins in disputed periods\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\u003ch2\u003eDexCom, Inc. - Canvas Business Model: Revenue Streams\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003e$3.62 billion\u003c\/strong\u003e in total revenue in 2023 came mainly from continuous glucose monitoring sensor sales and related consumables.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRevenue stream\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eReal-life disclosed numbers\u003c\/strong\u003e\u003c\/td\u003e\n \u003ctd\u003e\u003cstrong\u003eWhat it means for revenue\u003c\/strong\u003e\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG7 sensor sales\u003c\/td\u003e\n\u003ctd\u003eG7 launched in the U.S. in December 2022; DexCom reported total 2023 revenue of \u003cstrong\u003e$3.62 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003ctd\u003ePrimary growth engine as the newer CGM platform replaces older systems\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG6 legacy sensor sales\u003c\/td\u003e\n\u003ctd\u003eG6 remained a marketed product alongside G7 in 2023 and 2024\u003c\/td\u003e\n \u003ctd\u003eStill contributes revenue from an installed base that had not fully migrated to G7\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStelo biosensor sales\u003c\/td\u003e\n\u003ctd\u003eStelo received U.S. FDA clearance in March 2024\u003c\/td\u003e\n \u003ctd\u003eOpens a direct-to-consumer, over-the-counter revenue stream\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDexcom Flex sales\u003c\/td\u003e\n\u003ctd\u003eDexcom introduced Dexcom Flex in 2024\u003c\/td\u003e\n\u003ctd\u003eSupports subscription-style or flexible access purchases for consumers\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReimbursed CGM device revenue\u003c\/td\u003e\n\u003ctd\u003eDexCom reported \u003cstrong\u003e2023 revenue growth of 24%\u003c\/strong\u003e year over year\u003c\/td\u003e\n \u003ctd\u003ePayer and pharmacy reimbursement remains the largest commercialization route for CGM adoption\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eG7 sensor sales\u003c\/strong\u003e are the clearest core revenue stream. DexCom's G7 platform is the company's newest mass-market CGM system, and its launch in the U.S. in December 2022 shifted sales toward the newer product set in 2023 and 2024. Because DexCom does not publicly break out revenue by G7 alone, the best hard figure available is companywide revenue, which reached \u003cstrong\u003e$3.62 billion\u003c\/strong\u003e in 2023. That scale matters because the company's revenue model depends on recurring sensor replacement, not one-time device sales.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eRecurring sensor use drives repeat purchases.\u003c\/li\u003e\n \u003cli\u003eEach new user can generate multiple sensor purchases per year.\u003c\/li\u003e\n \u003cli\u003eG7 matters because it sits at the center of DexCom's replacement cycle.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eG6 legacy sensor sales\u003c\/strong\u003e still matter because DexCom continued to sell G6 after G7 entered the market. That means revenue did not switch overnight from one product to another. The legacy stream helps keep revenue stable during migration, especially for users, payers, and clinicians that remain on older stocked systems. DexCom has not publicly disclosed separate G6 sales revenue, so you can only state that G6 remained part of the marketed portfolio in 2023 and 2024.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eStelo biosensor sales\u003c\/strong\u003e create a different revenue path because Stelo was cleared by the U.S. FDA in March 2024 for adults not using insulin. That matters strategically because it opens access to a consumer market outside traditional prescription-heavy CGM reimbursement. DexCom has not publicly disclosed Stelo revenue as a separate number in the available filings through mid-2024, so no product-specific sales amount should be stated without a later filing.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eFDA clearance date: \u003cstrong\u003eMarch 2024\u003c\/strong\u003e\n\u003c\/li\u003e\n \u003cli\u003eTarget users: adults not using insulin\u003c\/li\u003e\n\u003cli\u003eRevenue logic: direct consumer access instead of only reimbursed prescription channels\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eDexcom Flex sales\u003c\/strong\u003e add a purchase structure that can lower friction for users who want access without a traditional full commitment at the point of sale. DexCom introduced Dexcom Flex in 2024. The company has not publicly disclosed separate Flex revenue in the available financial reporting through mid-2024, so the only factual statement you can make is that it represents a commercial access model layered on top of the CGM product base.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eReimbursed CGM device revenue\u003c\/strong\u003e remains the largest structural channel because CGM is a prescription-driven medical device business in many markets. DexCom's 2023 revenue was \u003cstrong\u003e$3.62 billion\u003c\/strong\u003e, up \u003cstrong\u003e24%\u003c\/strong\u003e from the prior year. That growth rate shows that reimbursement-backed demand was still scaling strongly. In academic writing, this stream matters because it links revenue to payer coverage, pharmacy benefit access, and doctor adoption rather than only to consumer demand.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eMetric\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003ePeriod\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.62 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYear-over-year revenue growth\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e24%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2023 vs. 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG7 U.S. launch\u003c\/td\u003e\n\u003ctd\u003eDecember 2022\u003c\/td\u003e\n\u003ctd\u003eLaunch timing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStelo FDA clearance\u003c\/td\u003e\n\u003ctd\u003eMarch 2024\u003c\/td\u003e\n\u003ctd\u003eLaunch-enabling regulatory milestone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDexcom Flex introduction\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003eCommercial model change\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFor a Business Model Canvas, these revenue streams show a company built on repeatable product consumption. The relevant number is not a one-time device sale; it is the recurring purchase cycle created by sensor replacement, payer reimbursement, and new consumer channels. That is why \u003cstrong\u003e$3.62 billion\u003c\/strong\u003e in 2023 revenue is better understood as a recurring-use model than as a hardware-only model.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":44601594019989,"sku":"dxcm-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/dxcm-business-model-canvas.png?v=1740166541","url":"https:\/\/dcf-model.com\/products\/dxcm-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}